Reading BRAF V600E from Plasma: What a Drop of ctDNA Can (and Can't) Tell You

The clinical question

When an oncologist orders a BRAF V600E test, the underlying question is deceptively simple: does this tumor carry the single amino-acid substitution—valine to glutamate at codon 600—that flips the BRAF kinase into a constitutively active state? The answer carries real weight. In metastatic colorectal cancer (mCRC), BRAF V600E is both a marker of poorer prognosis and a gate to a specific therapeutic class: BRAF-inhibitor combinations paired with anti-EGFR antibodies. In metastatic non–small cell lung cancer (NSCLC), the same mutation opens the door to combined BRAF- plus MEK-inhibitor therapy as a first-line option.

Historically that question was answered from tissue—an FFPE block interrogated by next-generation sequencing (NGS), PCR, or the VE1 immunohistochemistry antibody. But tissue isn't always available, adequate, or safely re-obtainable, especially in patients who are frail or whose accessible lesions are exhausted. That's the gap a plasma assay fills: can we read BRAF V600E status from circulating tumor DNA (ctDNA) shed into the bloodstream, and trust the result enough to make a therapy-class decision?

What's measured, and how

The analyte is cell-free DNA circulating in plasma, of which some fraction—often a very small fraction—is tumor-derived ctDNA. The target is the BRAF c.1799T>A variant that produces V600E. Modern regulatory-grade liquid biopsy assays detect it by massively parallel sequencing of a curated gene panel, with molecular barcoding and bioinformatic error suppression to distinguish a genuine low-frequency variant from sequencing noise.

Two points deserve emphasis for anyone interpreting these reports. First, sensitivity is context-dependent. ctDNA shedding varies with tumor burden, site of disease, and biology; a patient with low-volume or predominantly pulmonary disease may shed little detectable ctDNA. Second—and this is the interpretive linchpin—a plasma assay has an asymmetric error profile. A detected V600E is highly informative. A not-detected result is harder to act on, because you can't distinguish "the tumor is wild-type" from "the tumor simply isn't shedding enough ctDNA to clear the assay's limit of detection." This is why the prevailing practice, and the framing in the regulatory labeling, treats a negative plasma result as a prompt to reflex to tissue rather than a definitive wild-type call. The evidence suggests plasma is best used to rule in an actionable mutation quickly, not to rule one out.

The evidence

The clearest validation has come through the companion-diagnostic (CDx) pathway, where analytical and clinical performance are scrutinized against a therapeutic indication.

In lung cancer, the FDA approved both FoundationOne CDx (tissue) and FoundationOne Liquid CDx (plasma ctDNA) in May 2024 as companion diagnostics to identify BRAF V600E alterations in metastatic NSCLC for the encorafenib-plus-binimetinib combination [4]. That approval matters because it placed a plasma assay on regulatory footing alongside tissue for selecting patients for a BRAF/MEK-inhibitor class regimen—an option in the first-line setting for V600E-positive disease.

Colorectal cancer followed, and the sequence of 2026 approvals is worth reading together. In January 2026 the FDA granted traditional (full) approval to encorafenib for BRAF V600E-mutant metastatic colorectal cancer, converting what had been an accelerated approval into a durable indication—and, critically, its companion-diagnostic requirement explicitly encompasses ctDNA/plasma testing as an alternative to tissue [1]. On the diagnostic side, Guardant360 CDx—a plasma ctDNA NGS assay—received FDA approval as the companion diagnostic for the encorafenib combination in BRAF V600E-mutant mCRC, making it the first liquid biopsy CDx cleared specifically for encorafenib-based therapy selection in this setting [2]. The primary evidentiary basis is laid out in the FDA's Summary of Safety and Effectiveness Data for PMA supplement P200010/S026, with the notice of approval dated January 15, 2026, documenting the analytical and clinical validation supporting plasma-based V600E detection in mCRC [3].

Taken as a whole, this body of work establishes something important for practice: for the specific question of identifying a BRAF V600E mutation to enable a targeted regimen, plasma ctDNA has cleared the regulatory bar in both mCRC and NSCLC. The concordance and clinical performance behind these approvals underpin the CDx claims [2][3][4]. What these approvals do not do is redefine the meaning of a negative plasma result, and the labeling structure reflects that limitation.

Where it stands

For the predictive, therapy-linked question—can I use plasma to select a patient for a BRAF-inhibitor-based combination?—the answer is now firmly in the validated column for both metastatic colorectal cancer [1][2][3] and metastatic NSCLC [4]. A clinician can reasonably order a validated liquid biopsy CDx to detect BRAF V600E, and a positive result establishes eligibility for the relevant drug class. Where tissue is scarce or the patient can't tolerate a repeat biopsy, this is a genuine and welcome expansion of access.

Several caveats keep this measured. A negative or "not detected" plasma result should generally trigger tissue confirmation rather than a wild-type conclusion, because plasma sensitivity depends on ctDNA shed. The other clinical uses of BRAF V600E status—its role as an adverse prognostic marker in mCRC, and its use, alongside MLH1 promoter methylation, to help triage MLH1-deficient tumors away from a Lynch syndrome workup—are not what these plasma CDx approvals were validated for, and shouldn't be assumed to carry the same regulatory standing on ctDNA.

Finally, the fast-moving frontier: using serial ctDNA to detect minimal (or molecular) residual disease and to guide escalation or de-escalation of therapy. That application is conceptually attractive and under active study, but it remains investigational for BRAF V600E in these settings and sits outside the current CDx claims. The approvals discussed here validate plasma for detecting the mutation to select therapy—not for MRD-guided decision-making.

The practical bottom line: liquid biopsy for BRAF V600E has matured from a convenient adjunct into a regulatory-grade route to a treatment-class decision in both mCRC and NSCLC. Use a positive result with confidence; treat a negative one with appropriate humility.

---

References

1. U.S. Food and Drug Administration. FDA grants traditional approval to encorafenib for metastatic colorectal cancer with a BRAF V600E mutation. FDA Drugs — Resources & Information for Approved Drugs; 2026. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-traditional-approval-encorafenib-metastatic-colorectal-cancer-braf-v600e-mutation

2. Guardant Health, Inc. Guardant Health Receives FDA Approval for Guardant360 CDx as Companion Diagnostic for BRAFTOVI (encorafenib) Combination in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer. Guardant Health Investor Relations / Business Wire Press Release; 2026. https://investors.guardanthealth.com/press-releases/press-releases/2026/Guardant-Health-Receives-FDA-Approval-for-Guardant360-CDx-as-Companion-Diagnostic-for-BRAFTOVI-encorafenib-Combination-in-Patients-with-BRAF-V600E-Mutant-Metastatic-Colorectal-Cancer/default.aspx

3. U.S. Food and Drug Administration, Center for Devices and Radiological Health. Summary of Safety and Effectiveness Data (SSED): Guardant360 CDx, PMA P200010/S026. FDA CDRH — Premarket Approval Database; 2026. https://www.accessdata.fda.gov/cdrh_docs/pdf20/P200010S026B.pdf

4. Foundation Medicine, Inc. FDA Approves FoundationOne CDx and FoundationOne Liquid CDx as Companion Diagnostics for BRAFTOVI (encorafenib) in Combination With MEKTOVI (binimetinib) to Identify Patients with BRAF V600E Alterations in Metastatic NSCLC. Foundation Medicine Press Release; 2024. https://www.foundationmedicine.com/press-release/fda-approves-foundationonercdx-and-foundationonerliquid-cdx-companion-diagnostics